Management of Acute Periorbital Stroke with Interatrial Shunt
For a patient with acute ischemic stroke and an interatrial shunt on transthoracic echo, you should obtain a TEE to fully characterize the shunt and guide treatment decisions, then pursue percutaneous closure if the patient meets specific criteria (age 18-60, nonlacunar embolic stroke, PFO deemed causal after thorough workup), otherwise use antiplatelet or anticoagulant therapy based on individual risk factors.
Diagnostic Approach: Role of TEE
TEE is essential for complete evaluation after TTE identifies an interatrial shunt, as it provides superior characterization of PFO features that determine causality and treatment strategy 1.
TEE yields treatment-relevant findings in approximately 19% of patients with undetermined stroke cause, with an additional 6.4% of patients having findings not detected on TTE alone 2.
Key features to assess on TEE include: shunt size (quantified by microbubble count), presence of atrial septal aneurysm (>10mm excursion), spontaneous echo contrast, left atrial/appendage thrombus, and complex aortic atheroma 1.
TEE is particularly high-yield in younger patients, revealing treatment-relevant findings in approximately 14% of patients ≤60 years 2.
Decision Algorithm: Closure vs. Medical Therapy
Criteria for PFO Closure (All Must Be Met)
PFO device closure plus long-term antiplatelet therapy is recommended when ALL of the following are present 1:
- Age 18-60 years 1
- Nonlacunar embolic ischemic stroke confirmed by imaging (or TIA with positive neuroimaging/cortical symptoms) 1
- PFO deemed most likely cause after thorough etiological evaluation by neurologist/stroke expert excluding alternate etiologies 1
- High-risk PFO features: Large shunt (>30 microbubbles or moderate-to-large shunt) and/or atrial septal aneurysm 1
- No indication for long-term anticoagulation for other reasons 1
Evidence Supporting Closure
The CLOSE trial demonstrated 0% stroke recurrence with closure vs. 6.0% with antiplatelet therapy alone (HR 0.03, NNT=20 over 5 years) in carefully selected patients 1.
The REDUCE trial showed 1.4% stroke recurrence with closure vs. 5.4% with antiplatelet therapy (HR 0.23, NNT=28 over 2 years) 1.
Procedural risks include: atrial fibrillation in 4.6-6.6% (mostly transient), and serious device-related adverse events in 1.4-5.9% 1.
Medical Therapy When Closure Not Indicated
Antiplatelet Therapy
For patients >60 years or when PFO likely incidental: antiplatelet therapy alone is recommended for secondary prevention 1.
For patients ≤60 years with PFO-attributed stroke who do not undergo closure, either antiplatelet or anticoagulant therapy is reasonable 1.
Anticoagulation Indications
Anticoagulation is reasonable for high-risk patients with underlying hypercoagulable state or evidence of venous thrombosis 1.
If left atrial/ventricular thrombus is detected on TEE: anticoagulation for at least 3 months is recommended regardless of PFO status 1.
For patients requiring long-term anticoagulation for other indications (e.g., atrial fibrillation, hypercoagulable state): the decision regarding PFO closure remains unclear and should be based on individual risk-benefit assessment 1.
Critical Pitfalls to Avoid
Do not pursue closure in patients >60 years: evidence shows no benefit and PFO is likely incidental in this age group 1.
Do not close PFO without comprehensive stroke workup: must exclude other etiologies including atrial fibrillation (including paroxysmal), carotid disease, hypercoagulable states, and other cardioembolic sources 1.
Do not assume all PFOs are pathogenic: PFO prevalence is 25% in general population, making incidental findings common 1.
Beware of post-procedural atrial fibrillation: occurs in 4.6-6.6% after closure and may require anticoagulation, potentially negating the benefit of closure 1.